Literature DB >> 19197197

Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.

Hyoung Su Kim1, Ji Won Park, Ji Sun Jang, Ha Jung Kim, Woon Geon Shin, Kyung Ho Kim, Jin Heon Lee, Hak Yang Kim, Myoung Kuk Jang.   

Abstract

BACKGROUND/AIM: Alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) are most widely used tumor markers in detecting hepatocellular carcinoma (HCC). Recently, there have been some studies about them as prognostic markers in hepatitis C virus-associated HCC. However, prognostic values of AFP and PIVKA-II remain clarified in hepatitis B virus (HBV)-associated HCC. This study was aimed to evaluate the prognostic values of AFP and PIVKA-II in HBV-associated HCC.
METHODS: Patients (n=126) were divided into 4 groups according to median levels of AFP and PIVKA-II (L; low/low, A; high/low, P; low/high, H; high/high) at diagnosis. Clinical characteristics and survival were compared among the groups, and Cox regression analysis was performed to find independent factors for survival.
RESULTS: Baseline host and viral factors were not significantly different among the 4 groups. High PIVKA-II groups (P and H) had more aggressive tumor characteristics (larger size of tumors, higher number of tumors, frequent portal vein thrombosis, P<0.05) and much shorter median survival time than low PIVKA-II groups (L and A) (P<0.05). In multivariate analysis, high PIVKA-II level was an independent predictor for survival (risk ration: 2.377, 95% confidence interval: 1.359-4.157, P=0.002) together with Child-Pugh score, advanced TMN stages, and treatment modality. Even after excluding 33 patients who had Child-Pugh class C and advanced tumor stages (tumor-nodes-metastasis stage III-IV) at diagnosis, high PIVKA-II level was still an independent predictor for survival (risk ration: 4.258, 95% confidence interval: 2.418-8.445, P<0.001).
CONCLUSIONS: Serum PIVKA-II level, not serum AFP, was a valuable independent prognostic factor in HBV-related HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19197197     DOI: 10.1097/MCG.0b013e318182015a

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  24 in total

1.  Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma.

Authors:  Seungtaek Lim; Soohyeon Lee; Jae Yun Lim; Ji Soo Park; Jin Sil Seong; Won Seok Chang; Kwang-Hyub Han; Hye Jin Choi
Journal:  J Neurooncol       Date:  2014-07-26       Impact factor: 4.130

2.  Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.

Authors:  Atsushi Nanashima; Naota Taura; Takafumi Abo; Tatsuki Ichikawa; Ichiro Sakamoto; Takeshi Nagayasu; Kazuhiko Nakao
Journal:  Dig Dis Sci       Date:  2011-06-25       Impact factor: 3.199

3.  Presentation and outcomes of hepatocellular carcinoma patients at a western centre.

Authors:  Krit Kitisin; Vignesh Packiam; Jennifer Steel; Abhinav Humar; T Clark Gamblin; David A Geller; J Wallis Marsh; Allan Tsung
Journal:  HPB (Oxford)       Date:  2011-08-11       Impact factor: 3.647

4.  Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.

Authors:  Makoto Meguro; Toru Mizuguchi; Toshihiko Nishidate; Kenji Okita; Masayuki Ishii; Shigenori Ota; Tomomi Ueki; Emi Akizuki; Koichi Hirata
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

Review 5.  Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future.

Authors:  Arturo Soriano; Aranzazu Varona; Rajesh Gianchandani; Modesto Enrique Moneva; Javier Arranz; Antonio Gonzalez; Manuel Barrera
Journal:  World J Hepatol       Date:  2016-01-08

6.  Serum alpha-fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resection.

Authors:  Yeshika Sharma; Michael J Weaver; Daniel R Ludwig; Kathryn Fowler; Neeta Vachharajani; William C Chapman; Jeffrey S Crippin
Journal:  Surgery       Date:  2017-12-25       Impact factor: 3.982

7.  Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Do Seon Song; Si Hyun Bae; Myeong Jun Song; Sung Won Lee; Hee Yeon Kim; Young Joon Lee; Jung Suk Oh; Ho Jong Chun; Hae Giu Lee; Jong Young Choi; Seung Kew Yoon
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

8.  Preoperative prognostic values of α-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation.

Authors:  Seok-Hwan Kim; Deok-Bog Moon; Wan-Joon Kim; Woo-Hyoung Kang; Jae Hyun Kwon; Eun Kyung Jwa; Hwui-Dong Cho; Su-Min Ha; Yong-Kyu Chung; Sung-Gyu Lee
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

9.  Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma.

Authors:  Bal Krishan Sharma; Radhika Srinivasan; Shweta Kapil; Bhupesh Singla; Nitin Saini; Yogesh Kumar Chawla; Anuradha Chakraborti; Ajay Duseja; Naveen Kalra; Radha Krishan Dhiman
Journal:  Mol Cell Biochem       Date:  2013-08-04       Impact factor: 3.396

10.  Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma.

Authors:  Chang Liu; Guang-Qin Xiao; Lu-Nan Yan; Bo Li; Li Jiang; Tian-Fu Wen; Wen-Tao Wang; Ming-Qing Xu; Jia-Yin Yang
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.